Gossamer Bio (NASDAQ:GOSS) Coverage Initiated by Analysts at Chardan Capital

Analysts at Chardan Capital initiated coverage on shares of Gossamer Bio (NASDAQ:GOSS) in a research report issued on Tuesday, Marketbeat Ratings reports. The brokerage set a “buy” rating on the stock.

Several other analysts have also recently issued reports on GOSS. Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price on the stock in a research report on Tuesday, July 28th. Weiss Ratings upgraded Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a research report on Thursday, August 27th. Finally, Wall Street Zen cut Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Gossamer Bio currently has an average rating of “Hold” and a consensus price target of $256.00.

Gossamer Bio Stock Down 3.9%

GOSS stock traded down $0.34 during trading on Tuesday, hitting $8.43. 179,473 shares of the company’s stock traded hands, compared to its average volume of 242,096. The firm has a market capitalization of $51.51 million, a P/E ratio of -0.15 and a beta of 2.21. Gossamer Bio has a 1 year low of $8.31 and a 1 year high of $309.60. The business has a fifty day simple moving average of $11.92 and a two-hundred day simple moving average of $16.83.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Rockefeller Capital Management L.P. raised its holdings in shares of Gossamer Bio by 496.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 60,866 shares of the company’s stock worth $189,000 after buying an additional 50,666 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Gossamer Bio by 73.4% during the first quarter. SG Americas Securities LLC now owns 128,568 shares of the company’s stock valued at $42,000 after buying an additional 54,439 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Gossamer Bio during the first quarter valued at $38,000. ADAR1 Capital Management LLC acquired a new position in shares of Gossamer Bio in the 2nd quarter valued at $35,000. Finally, Hennion & Walsh Asset Management Inc. increased its position in shares of Gossamer Bio by 32.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 1,098,914 shares of the company’s stock valued at $181,000 after acquiring an additional 270,195 shares during the period. Hedge funds and other institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with disorders involving the immune system, inflammation and fibrosis. The company is headquartered in San Diego, California, and primarily operates through the development of its proprietary drug candidates and strategic collaborations.

Gossamer’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary vascular remodeling.